Interdependence of Molecular Lesions That Drive Uveal Melanoma Metastasis.
BAP1
CNA
gene expression
metastases
tumor evolution
uveal melanoma
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
26 Oct 2023
26 Oct 2023
Historique:
received:
28
09
2023
revised:
19
10
2023
accepted:
24
10
2023
medline:
15
11
2023
pubmed:
14
11
2023
entrez:
14
11
2023
Statut:
epublish
Résumé
The metastatic risk of uveal melanoma (UM) is defined by a limited number of molecular lesions, somatic mutations (SF3B1 and BAP1), and copy number alterations (CNA): monosomy of chromosome 3 (M3), chr8q gain (8q), chr6p gain (6p), yet the sequence of events is not clear. We analyzed data from three datasets (TCGA-UVM, GSE27831, GSE51880) with information regarding M3, 8q, 6p, SF3B1, and BAP1 status. We confirm that BAP1 mutations are always associated with M3 in high-risk patients. All other features (6p, 8q, M3, SF3B1 mutation) were present independently from each other. Chr8q gain was frequently associated with chr3 disomy. Hierarchical clustering of gene expression data of samples with different binary combinations of aggressivity factors shows that patients with 8q|M3, BAP1|M3 form one cluster enriched in samples that developed metastases. Patients with 6p combined with either 8q or SF3B1 are mainly represented in the other, low-risk cluster. Several gene expression events that show a non-significant association with outcome when considering single features become significant when analyzing combinations of risk features indicating additive action. The independence of risk factors is consistent with a random risk model of UM metastasis without an obligatory sequence.
Identifiants
pubmed: 37958591
pii: ijms242115602
doi: 10.3390/ijms242115602
pmc: PMC10648765
pii:
doi:
Substances chimiques
Tumor Suppressor Proteins
0
Ubiquitin Thiolesterase
EC 3.4.19.12
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministero della Salute
ID : 5M-2018- 23680288
Organisme : Ricerca corrente
ID : NA
Références
Cancer. 2018 Sep 1;124(17):3490-3499
pubmed: 29663336
Cancers (Basel). 2019 Aug 07;11(8):
pubmed: 31394860
Bioinformatics. 2014 Oct;30(19):2811-2
pubmed: 24930139
Eur J Cancer. 2013 Oct;49(15):3353-65
pubmed: 23849826
Cancer Discov. 2022 Dec 2;12(12):2856-2879
pubmed: 36098958
Am J Hum Genet. 2016 Nov 3;99(5):1190-1198
pubmed: 27745836
Cancer Cell Int. 2021 Dec 19;21(1):686
pubmed: 34923990
Cancer Res. 2004 Oct 15;64(20):7205-9
pubmed: 15492234
Ophthalmology. 2016 May;123(5):1118-28
pubmed: 26923342
Cancer Cell. 2013 Oct 14;24(4):410-21
pubmed: 24135279
Br J Ophthalmol. 2014 Dec;98(12):1738-43
pubmed: 25147369
Indian J Ophthalmol. 2021 Jul;69(7):1839-1845
pubmed: 34146040
Cancer Metastasis Rev. 2016 Mar;35(1):63-74
pubmed: 26947218
Drug Des Devel Ther. 2023 Feb 07;17:333-339
pubmed: 36785760
Commun Med (Lond). 2023 Apr 28;3(1):60
pubmed: 37117276
Nat Genet. 2015 Mar;47(3):209-16
pubmed: 25665006
Cancers (Basel). 2021 Nov 13;13(22):
pubmed: 34830841
N Engl J Med. 2010 Dec 2;363(23):2191-9
pubmed: 21083380
Innovation (Camb). 2021 Jul 01;2(3):100141
pubmed: 34557778
Cells. 2019 May 20;8(5):
pubmed: 31137555
Biomedicines. 2022 Dec 13;10(12):
pubmed: 36551996
Sci Rep. 2021 Aug 17;11(1):17036
pubmed: 34404859
Clin Cancer Res. 2019 Sep 15;25(18):5513-5524
pubmed: 31227496
PLoS One. 2012;7(1):e29989
pubmed: 22267972
Cancers (Basel). 2022 Jul 28;14(15):
pubmed: 35954340
Cancer Cell. 2017 Aug 14;32(2):204-220.e15
pubmed: 28810145
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Ophthalmol Sci. 2022 Jan 30;2(2):100121
pubmed: 36249692
Oncotarget. 2016 Jan 26;7(4):4624-31
pubmed: 26683228
Cancer Metastasis Rev. 2008 Mar;27(1):75-83
pubmed: 18046511
Cell. 2013 Nov 7;155(4):948-62
pubmed: 24183448
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Nat Commun. 2021 Sep 13;12(1):5402
pubmed: 34518527
Ophthalmology. 2022 Apr;129(4):431-437
pubmed: 34793831
Nature. 2009 Jan 29;457(7229):599-602
pubmed: 19078957
BMC Bioinformatics. 2012 Dec 24;13:335
pubmed: 23259851
Eur J Cancer. 2022 Jul;170:27-41
pubmed: 35580369
Cancer Metastasis Rev. 2017 Mar;36(1):109-140
pubmed: 28229253
Cell. 2015 Jun 18;161(7):1681-96
pubmed: 26091043
Bioinformatics. 2016 Sep 15;32(18):2847-9
pubmed: 27207943
NPJ Genom Med. 2021 Aug 16;6(1):70
pubmed: 34400647
N Engl J Med. 2015 Nov 12;373(20):1926-36
pubmed: 26559571
J Clin Med. 2020 Feb 03;9(2):
pubmed: 32028647
BMC Med Genomics. 2022 Mar 17;15(1):61
pubmed: 35300699
Cancers (Basel). 2019 Oct 30;11(11):
pubmed: 31671564
BMC Med Genet. 2014 Mar 05;15:29
pubmed: 24597767
Invest Ophthalmol Vis Sci. 2009 Jun;50(6):2572-80
pubmed: 19151381
Nat Rev Dis Primers. 2020 Apr 9;6(1):24
pubmed: 32273508
J Ultrasound Med. 1983 Sep;2(9):425-7
pubmed: 6632071
Cancer Cell. 2023 Aug 14;41(8):1466-1479.e9
pubmed: 37541243
Invest Ophthalmol Vis Sci. 2020 Apr 9;61(4):35
pubmed: 32334433
BMC Bioinformatics. 2008 Dec 29;9:559
pubmed: 19114008
Nat Commun. 2018 Jan 9;9(1):116
pubmed: 29317634
Cancers (Basel). 2019 Sep 26;11(10):
pubmed: 31561508
Bioinformatics. 2019 Sep 15;35(18):3348-3356
pubmed: 30698637
J Immunother Cancer. 2019 Nov 13;7(1):299
pubmed: 31722735
Prog Retin Eye Res. 2020 Mar;75:100800
pubmed: 31563544